{"id":915809,"date":"2025-12-03T12:17:13","date_gmt":"2025-12-03T17:17:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum\/"},"modified":"2025-12-03T12:17:13","modified_gmt":"2025-12-03T17:17:13","slug":"longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum\/","title":{"rendered":"Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum"},"content":{"rendered":"
\n

MIAMI, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) — Longeveron Inc.<\/a> (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that its Chief Science Officer, Dr. Joshua Hare<\/a>, and Chief Medical Officer, Dr. Nataliya Agafonova<\/a>, will speak on multiple panel discussions at the Global CardioVascular Clinical Trialists (CVCT) Forum<\/a> taking place December 8-10, 2025 in Washington, D.C. The CVCT Forum seeks to promote rigorous evidence generation and accelerate the global impact of cardiovascular clinical trials.<\/p>\n

\n Panel Discussions \u2013 December 8, 2025<\/strong>\n <\/p>\n

\n Cell Therapy Heart Failure Trials \u2013 Cells Deliver and Disease Specific Strategies<\/u>
\n
\n Is Cell Delivery Route Important?<\/em>
\n
Intravenous Delivery of Cells\/Cell Products: The Magic Bullet? Dr. Joshua Hare<\/p>\n

\n What Type of Cells?<\/em>
\n
Mesenchymal Stem Cell Therapy for Dilated Cardiomyopathy: Lessons from POSEIDON and the PATH AHEAD \u2013 Dr. Joshua Hare<\/p>\n

\n How to Streamline Cell Therapy Innovation, Not Compromising the Level of Evidence<\/u>
\n
\n The CVCT Multi-Stakeholder Think Tank Debate<\/em>
\n
Dr. Nataliya Agafonova, Panelist<\/p>\n

\n About Longeveron Inc.<\/strong>\n <\/p>\n

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company\u2019s lead investigational product is laromestrocel (Lomecel-B\u00ae), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer\u2019s disease, and Pediatric Dilated Cardiomyopathy (DCM). Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program – Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program – Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit\u00a0www.longeveron.com<\/a>\u00a0or follow Longeveron on\u00a0LinkedIn<\/a>,\u00a0X<\/a>, and\u00a0Instagram<\/a>.<\/p>\n

\n Investor and Media Contact:<\/strong>
\n
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com<\/a><\/p>\n

Photos accompanying this announcement are available at
https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/e9e96d9c-d6c3-4aec-ba85-36631b520211<\/a>
https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/f106bde7-972a-4687-a91e-03e924f409fc<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

MIAMI, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that its Chief Science Officer, Dr. Joshua Hare, and Chief Medical Officer, Dr. Nataliya Agafonova, will speak on multiple panel discussions at the Global CardioVascular Clinical Trialists (CVCT) Forum taking place December 8-10, 2025 in Washington, D.C. The CVCT Forum seeks to promote rigorous evidence generation and accelerate the global impact of cardiovascular clinical trials. Panel Discussions \u2013 December 8, 2025 Cell Therapy Heart Failure Trials \u2013 Cells Deliver and Disease Specific Strategies Is Cell Delivery Route Important? Intravenous Delivery of Cells\/Cell Products: The Magic Bullet? Dr. Joshua Hare What … <\/p>\n

Continue reading “Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-915809","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nLongeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MIAMI, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that its Chief Science Officer, Dr. Joshua Hare, and Chief Medical Officer, Dr. Nataliya Agafonova, will speak on multiple panel discussions at the Global CardioVascular Clinical Trialists (CVCT) Forum taking place December 8-10, 2025 in Washington, D.C. The CVCT Forum seeks to promote rigorous evidence generation and accelerate the global impact of cardiovascular clinical trials. Panel Discussions \u2013 December 8, 2025 Cell Therapy Heart Failure Trials \u2013 Cells Deliver and Disease Specific Strategies Is Cell Delivery Route Important? Intravenous Delivery of Cells\/Cell Products: The Magic Bullet? Dr. Joshua Hare What … Continue reading "Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-03T17:17:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTkwNCM3MzAzNTE4IzIyMDcwNjA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum\",\"datePublished\":\"2025-12-03T17:17:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum\\\/\"},\"wordCount\":376,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTkwNCM3MzAzNTE4IzIyMDcwNjA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum\\\/\",\"name\":\"Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTkwNCM3MzAzNTE4IzIyMDcwNjA=\",\"datePublished\":\"2025-12-03T17:17:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTkwNCM3MzAzNTE4IzIyMDcwNjA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTkwNCM3MzAzNTE4IzIyMDcwNjA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum\/","og_locale":"en_US","og_type":"article","og_title":"Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum - Market Newsdesk","og_description":"MIAMI, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that its Chief Science Officer, Dr. Joshua Hare, and Chief Medical Officer, Dr. Nataliya Agafonova, will speak on multiple panel discussions at the Global CardioVascular Clinical Trialists (CVCT) Forum taking place December 8-10, 2025 in Washington, D.C. The CVCT Forum seeks to promote rigorous evidence generation and accelerate the global impact of cardiovascular clinical trials. Panel Discussions \u2013 December 8, 2025 Cell Therapy Heart Failure Trials \u2013 Cells Deliver and Disease Specific Strategies Is Cell Delivery Route Important? Intravenous Delivery of Cells\/Cell Products: The Magic Bullet? Dr. Joshua Hare What … Continue reading \"Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-03T17:17:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTkwNCM3MzAzNTE4IzIyMDcwNjA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum","datePublished":"2025-12-03T17:17:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum\/"},"wordCount":376,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTkwNCM3MzAzNTE4IzIyMDcwNjA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum\/","name":"Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTkwNCM3MzAzNTE4IzIyMDcwNjA=","datePublished":"2025-12-03T17:17:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTkwNCM3MzAzNTE4IzIyMDcwNjA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTkwNCM3MzAzNTE4IzIyMDcwNjA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-global-cardiovascular-clinical-trialists-cvct-forum\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/915809","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=915809"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/915809\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=915809"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=915809"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=915809"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}